Golwas Douglas P 4

What Happened

• Douglas P. Golwas, Chief Commercial Officer of Medline (MDLN), received a series of awards and reclassified ownership interests tied to Medline Holdings, LP. The filings show grants/acquisitions on 2025-12-16 (multiple tranches) and an additional grant on 2026-03-05 for 25,788 shares at $0.00. The combined reported quantities across the entries total roughly 2.9 million shares/units. These were awards/reclassifications (transaction code A) rather than open-market purchases or sales; most are derivative/incentive interests or restricted units rather than immediate cash purchases.

Key Details

• Primary transaction dates: 2025-12-16 (multiple award/reclassification entries) and 2026-03-05 (25,788 shares @ $0.00).
• Reported quantities (by line items): 465,864; 465,864 (derivative); 948,597 (derivative); 463,211 (derivative); 212,755 (derivative); 157,800 (derivative); 149,005 (derivative); plus 25,788 (acquired 3/5/2026). Combined ≈ 2,888,884 units.
• Price/cash: No cash purchase reported; many items show N/A or $0.00 — these are grants/reclassifications.
• Shares owned after transaction: not specified in the provided filing details.
• Notable footnotes:
  • Several securities were acquired via reclassification of Medline Holdings, LP interests prior to Medline’s IPO (previously reported on the insider’s Form 3).
  • Many items are Incentive Units (profit‑interest style awards) that can be converted to Common Units and then exchanged for Class A common stock under an exchange agreement; conversion depends on thresholds and public share price.
  • Class B common stock referenced carries one vote per share but “no economic value” and cancels upon exchange for Class A shares.
  • Vesting varies by tranche: examples include partially vested tranches (20% vested; 40% vested; 70% vested), tranches that vest over five equal annual installments, and some fully vested awards. Some RSUs have 25% vesting on a near-term date with the remainder in annual installments.
  • Some securities are held in a trust for which the reporting person is trustee.
• Filing timeliness: The Form 4 was filed on 2026-03-06 while the primary reported transactions occurred on 2025-12-16 — the filing appears late (filed roughly 2.5 months after the reported transactions).

Context

• These entries are awards and reclassifications tied to pre-IPO interests and incentive units, not open-market purchases or sales. Incentive Units are derivative-like (similar to stock appreciation rights) and require conversion and/or vesting to become exchangeable for publicly traded Class A shares. Because many tranches have vesting schedules or conversion conditions, these awards do not necessarily represent immediately marketable shares.
• For retail investors: awards/grants show management compensation and alignment with the company but are not the same as an insider buying shares on the open market (which some investors view as a stronger bullish signal). The late filing means the market saw these transactions only after a delay.